Harbour BioMed (HBM), a global biopharmaceutical company focused on innovative antibody therapeutics in immunology and oncology, has entered into a strategic collaboration with Evinova, a global health-tech company dedicated to advancing digital health solutions for the life sciences sector. The partnership aims to leverage artificial intelligence (AI) and digital technologies to accelerate and enhance the efficiency of biologics research and development.

Under the collaboration, Harbour BioMed and Evinova China will jointly apply AI-driven tools and digital platforms to streamline the development of innovative biologics. The two companies plan to establish an open ecosystem that fosters collaboration and innovation in AI-powered drug discovery.

Dr. Jingsong Wang, founder, chairman, and CEO of Harbour BioMed, said the partnership will strengthen efforts to improve clinical study efficiency and accelerate the delivery of breakthrough therapies. Nate Zhang, general manager of Evinova China, added that Evinova’s AI-powered clinical development and strategy services will complement Harbour BioMed’s expertise, helping advance China-originated biotherapeutics to global markets.

Harbour BioMed specializes in developing novel antibody therapeutics, while Evinova focuses on driving digital transformation across the life sciences industry.